ENCINO, Calif., Feb. 2, 2009 — Secretropin(R), the first clinically proven natural stimulator of growth hormone production, is gaining the medical community’s acceptance as a more desirable “first step” approach to pursuing hormonal balance. Although classified as a natural food supplement, Secretropin(R) is only available through a prescribing physician due to its clinically proven ability to increase the body’s own production and release of growth hormone. This reproducible response of Secretropin’s(R) use is reflected in its recently posted 9-month retail sales record of $1M.
Developed in 2001, Secretropin(R) received early medical acknowledgement for 2 key reasons: one, its reproducible effectiveness; and two, its preferable oral delivery. In as little as 4 weeks Secretropin(R) has been shown to increase the production of growth hormone by 50 – 200% while being delivered as an oral spray. Secretropin’s(R) oral delivery system (ODS) owes its effectiveness to the latest nanoliposomal technology, which wraps the active agents in a protective envelop. Until this delivery technology was available, stomach acid would inactivate and destroy the active agents responsible for the increase in growth hormone production.
Prior to Secretropin(R), this left injectable growth hormone as the only other viable option. Fortunately, the nanoliposomal technology protects the complex, allowing for optimal absorption and leading to a more natural increase in growth hormone levels – thus eliminating the less desirable approach of daily injections.
On the financial side, the present global market for injectable human growth hormone (HGH) therapy is estimated to exceed $3B. The market is growing at a projected 15 to 20% rate as the world medical community recognizes the benefits to maintaining healthy hormone levels throughout life. Currently, injectable GH therapy costs approximately $1000/month, and with the technological advances captured by Secretropin(R), the cost range has been significantly reduced to between $150 and $200/month.
The Millennium Health Center, Inc. participated in the development of Secretropin(R) and provides ongoing clinical research (report). As of October 2006, there are over 3000 patient months of data being compiled by a number of independent centers throughout the U.S., Australia, New Zealand, India, Russia, Thailand, China, and Dubai. So far, Secretropin’s(R) ability to increase growth hormone production has been reported in excess of 95% of the cases.
The combination of known benefits of healthy levels of human growth hormone, plus Secretropin’s(R) clinically documented response rate, added to its cost-effectiveness, is what is being labeled as a responsible first-step approach to pursuing age-appropriate hormonal balanced therapy.
For additional information:
# # #